Oxford Gene Technology (OGT), which specialises in biomarker and microarray technologies, has acquired Maidenhead-based protein array firm Sense Proteomic for an undisclosed sum.

Oxford Gene Technology (OGT), which specialises in biomarker and microarray technologies, has acquired Maidenhead-based protein array firm Sense Proteomic for an undisclosed sum.

Sense Proteomic’s technology can identify a stage of disease by monitoring changes in autoantibody production during disease progression and can also be used to monitor response to therapeutic interventions.

OGT chief executive Mike Evans commented: “This deal, combined with our recent development of an ultra-high-throughput DNA microarray facility, gives OGT a unique blend of genomic and proteomic technologies and will lead to the development of biomarkers with profound clinical significance.”

Sense Proteomic CEO Rachel Fallon said: “This transaction represents a rare
opportunity to discover important biomarkers for disease using more than one approach. The biomarkers can be detected using a simple blood test for early diagnosis and prognosis of disease. We look forward to integrating with OGT’s current capabilities and microarray expertise.”